Group 1 - The controlling shareholder of the company, Shenzhen Baiye Yuan Investment Co., Ltd., holds 89,565.37 million shares, accounting for 48.96% of the total issued share capital of 182,945.34 million shares [2] - Baiye Yuan Investment has released a pledge of 19.50 million shares, which represents 2.18% of its holdings and 1.07% of the company's total issued shares [2] - After the release of the pledge, Baiye Yuan Investment has no pledged shares remaining [3] Group 2 - As of the announcement date, the cumulative pledged shares of the controlling shareholder, Baiye Yuan Investment, are zero following the recent release [3] - The company will continue to monitor the pledge and release status of the shares held by its shareholders and will comply with relevant disclosure obligations [3]

Core Points - On September 8, Health元 announced that its controlling shareholder, Shenzhen Baiye Yuan Investment Co., Ltd., will release the pledge of 19.5 million unrestricted circulating shares to the Industrial and Commercial Bank of China, Shenzhen Hongwei Branch, on September 5, 2025 [2] Summary by Category - **Company Announcement** - Health元 disclosed the release of a pledge involving 19.5 million shares [2] - The pledge release has been completed with the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [2] - **Shareholder Information** - The controlling shareholder involved in the pledge release is Shenzhen Baiye Yuan Investment Co., Ltd. [2]

Group 1 - Health元 announced the release of 19.5 million shares from pledge by 百业源投资 on September 5, 2023, with no subsequent pledge plans confirmed [1] - 百业源投资 holds approximately 896 million unrestricted circulating shares, accounting for 48.96% of the total issued share capital of Health元, which is about 1.829 billion shares [1] - For the first half of 2025, Health元's revenue composition shows that the pharmaceutical manufacturing sector accounts for 99.14%, while other businesses contribute 0.86% [1] Group 2 - As of the report, Health元's market capitalization is 24.5 billion yuan [2]

证券代码：600380 证券简称：健康元 公告编号：临 2025-065 健康元药业集团股份有限公司 关于股东部分股权解除质押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●健康元药业集团股份有限公司（以下简称：本公司）控股股东深圳市百业源投 资有限公司（以下简称：百业源投资）持有本公司无限售流通股 89,565.37 万股，占本 公司已发行总股本（182,945.34 万股）48.96%。 健康元药业集团 关于股东部分股权解除质押公告 | | | 占其所 | 占公司 | | | | 剩余被质 | 剩余被质 押股份数 | 剩余被质 押股份数 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东名称 | 本次解质 | 持股份 | 总股本 | 解质时间 | 持股数量 | 持股 | 押股份数 | 量占其所 | 量占公司 | | | 股份 | | | | | 比例 | | | | | | | 比例 | 比例 | | | | 量 ...

Group 1 - The core viewpoint of the articles highlights the performance and financial metrics of Health元, indicating a positive trend in stock price and market activity [1][2][3] - As of September 5, Health元's stock price increased by 2.05% to 13.44 CNY per share, with a total market capitalization of 24.588 billion CNY [1] - Year-to-date, Health元's stock has risen by 21.41%, with notable increases of 8.21% over the last five trading days, 9.62% over the last twenty days, and 17.28% over the last sixty days [1] Group 2 - Health元's main business segments include chemical preparations (47.71%), chemical raw materials and intermediates (31.97%), traditional Chinese medicine preparations (10.28%), diagnostic reagents and equipment (4.74%), health food (3.08%), biological products (1.20%), and others (0.86%) [1] - As of June 30, 2025, Health元 reported a revenue of 7.898 billion CNY, a year-on-year decrease of 4.08%, while net profit attributable to shareholders increased by 1.10% to 785 million CNY [2] - The company has distributed a total of 3.979 billion CNY in dividends since its A-share listing, with 1.04 billion CNY distributed in the last three years [3]

Core Viewpoint - The company has entered into guarantee agreements with Ping An Bank to support its wholly-owned subsidiaries, ensuring their operational financing needs are met without any related guarantees or overdue situations [1][9][10]. Group 1: Guarantee Details - The total guarantee amounts for the subsidiaries are as follows: Shenzhen Haibin Pharmaceutical Co., Ltd. (RMB 200 million), Shenzhen Taotai Pharmaceutical Co., Ltd. (RMB 80 million), Jiaozuo Health Yuan Biological Products Co., Ltd. (RMB 200 million), and Health Yuan Haibin Pharmaceutical Co., Ltd. (RMB 100 million) [1]. - The company has approved a maximum credit financing of RMB 24.6 billion or equivalent foreign currency from banks, with a specific guarantee of up to RMB 20.201 billion for its subsidiaries [2][9]. - The guarantees provided are joint liability guarantees, with no counter-guarantees involved [5][6][7][8]. Group 2: Financial Health and Risk Management - As of August 31, 2025, the total guarantee balance of the company is RMB 2.834 billion, which represents 19.50% of the latest audited net assets attributable to shareholders [10]. - There are no overdue guarantees for the company or its subsidiaries, indicating a stable financial position and effective risk management [10].

Group 1 - The company Health元 announced the signing of a guarantee agreement with Ping An Bank Shenzhen Branch [2] - The guaranteed parties include four wholly-owned subsidiaries of the company: Shenzhen Haibin Pharmaceutical Co., Ltd., Shenzhen Taotai Pharmaceutical Co., Ltd., Jiaozuo Health元 Biological Products Co., Ltd., and Health元 Haibin Pharmaceutical Co., Ltd. [2] - The total guarantee amounts are RMB 200 million, RMB 80 million, RMB 200 million, and RMB 100 million for each respective subsidiary [2]

健康元药业集团 担保进展公告 证券代码：600380 证券简称：健康元 公告编号：临 2025-064 健康元药业集团股份有限公司 关于为控股子公司提供担保进展情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 担保对象及基本情况 | | 被担保人名称 | 深圳市海滨制药有限公司 | | | | --- | --- | --- | --- | --- | | | 本次担保金额 | 20,000 万元 | | | | 担保对象一 | 实际为其提供的担保余额 | 万元 22,785.65 | | | | | 是否在前期预计额度内 | 是 □否 | | □不适用：_________ | | | 本次担保是否有反担保 | □是 否 | | □不适用：_________ | | 担保对象二 | 被担保人名称 | 深圳太太药业有限公司 | | | | | 本次担保金额 | 8,000 万元 | | | | | 实际为其提供的担保余额 | 万元 0.00 | | | | | 是否在前期预计额度内 | 是 □否 ...

Group 1 - The three major indices opened mixed, with the National Index of Free Cash Flow showing slight upward movement after initial fluctuations, driven by strong performances from component stocks like Silver and Jiejia Weichuang, which rose over 8% [1] - The largest ETF tracking the National Index of Free Cash Flow (159201) saw active trading, with transaction volume exceeding 110 million yuan, reflecting investor interest [1] - The probability of a Federal Reserve interest rate cut in September has significantly increased due to unexpected CPI data, which could lead to a shift in global capital flows [1] Group 2 - According to Kaiyuan Securities, the current bull market is supported by long-term factors including an impending bottom in the profit and economic cycle, with PPI expected to reverse and profit bottom likely to be reached within 2-3 quarters [2] - The funding environment is bolstered by the central government's support, establishing a market foundation, while mid-to-long-term patient capital has been built [2] - The Free Cash Flow ETF (159201) closely tracks the National Index of Free Cash Flow, selecting stocks with positive and high free cash flow after liquidity, industry, and ROE stability screening, making it suitable for long-term investment [2]

Core Insights - The China Securities Index Free Cash Flow Index (932365) has shown a positive performance, with a 0.86% increase as of September 2, 2025, and notable gains in constituent stocks such as Silver Nonferrous (601212) up by 10.08% and Jiejia Weichuang (300724) up by 8.93% [1] Performance Summary - The Free Cash Flow ETF Fund (159233) has experienced a 1.24% increase, marking its fourth consecutive rise, with a latest price of 1.14 yuan. Over the past two weeks, the fund has accumulated a total increase of 3.58% [1] - The fund's liquidity is reflected in a turnover rate of 1.07% and a trading volume of 1.2954 million yuan. The average daily trading volume over the past week was 17.6088 million yuan [1] - The fund has seen a net inflow of 19.1927 million yuan recently, with a total of 25.8568 million yuan net inflow over the last five trading days, averaging 5.1714 million yuan per day [1] Return Metrics - Since its inception, the Free Cash Flow ETF Fund has achieved a maximum monthly return of 7.80% and a longest consecutive monthly gain of 3 months, with a total increase of 12.56%. The average return during up months is 4.07%, with a monthly profit probability of 92% [2] - The maximum drawdown since inception is 3.28%, with a relative benchmark drawdown of 0.24%. The recovery period after drawdown is 12 days, indicating a relatively quick recovery compared to comparable funds [2] - The fund has a management fee of 0.50% and a custody fee of 0.10% [2] Top Holdings - As of August 29, 2025, the top ten weighted stocks in the China Securities Index Free Cash Flow Index include China National Offshore Oil Corporation (600938), Wuliangye (000858), and COSCO Shipping Holdings (601919), collectively accounting for 57.03% of the index [3]